A Phase IIa study of OPM-201 in patients with Parkinson's disease
Latest Information Update: 03 Apr 2024
At a glance
- Drugs S-221237 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2024 New trial record
- 26 Mar 2024 According to Oncodesign Precision Medicine media release, company expects to enter Phase IIa in patients with Parkinsons disease in 2025.